New Bisphenol A Study Is of Very Limited Relevance to Human Health
ARLINGTON, Va., June 17 /PRNewswire-USNewswire/ -- The following statement can be attributed to Steven G. Hentges, Ph.D. of the American Chemistry Council's (ACC) Polycarbonate/BPA Global Group. Dr. Hentges' comments are in regard to a study from researchers at North Carolina State University (...
FYI From Human Genome Sciences: GlaxoSmithKline Study Shows GSK's Novel Diabetes Treatment Syncria(R) (Albiglutide) Improves Glucose Control, Reduces Weight
ROCKVILLE, Md. , June 8 /PRNewswire-FirstCall/ -- Attached is a press release issued yesterday by GlaxoSmithKline (GSK), regarding new Phase 2 data for Syncria(R) (albiglutide) presented at the American Diabetes Association 69th Scientific Sessions in New Orleans.
Intercell AG Announces First Subject Enrolled in a Phase II Trial for the Further Development of Its Investigational Vaccine Enhancement Patch to Improve Pandemic Influenza Prevention in Collaboration With U.S. Department of Health and Human Services (HHS
- Phase II clinical trial investigating the effectiveness of Intercell's Vaccine Enhancement (VE) Patch in combination with an injectable H5N1 pandemic influenza vaccine started today in the U.S.
- The study is fully funded by HHS - this is the second study conducted under a 5 year USD 128 m ...
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338
-Clinical study planned for relapsed / refractory acute myelogenous leukemia-
PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX ) announced today the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FD...
Alimera Sciences Announces Presentation of Data From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study at ARVO 2009 Annual Meeting
ATLANTA, May 4 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that positive interim 12-month safety and efficacy results from the first ...
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human
Anti-PS Antibodies and Expand the Company's PS-Targeting Platform-
-Treatment with Mouse Equivalent to the Human
Antibody Inhibited Tumor Growth in a Prostate Cancer Model by More than 90%-
Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
Study Presented at 2009 AACR Meeting Highlights Potential Therapeutic Approach to Treat Patients Unresponsive to Erbitux and Vectibix
DENVER, April 22 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI ), a biopharmaceutical company developing novel, proprietary antibodies for the treat...
Pharmasset Initiates First Time in Human Study of PSI-7851 for the Treatment of Hepatitis C (HCV)
PRINCETON, N.J., March 31 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS ) announced today that dosing has started in a phase 1, single ascending dose (SAD) study in healthy volunteers with PSI-7851, a second generation nucleotide analog polymerase inhibitor of hepatitis C virus (HCV)....
First Human Study to Show 'Sun Chlorella A' Supports Heart Health
RICHMOND, Va., March 30 /PRNewswire/ -- A new study, published in the Journal of Medicinal Food, showed that consumption of as little as 8 grams (1/3 ounce) of "Sun Chlorella A" daily resulted in noticeable reductions in body fat percentage, serum total cholesterol, and fasting blood glucose lev...
Nobilon Advances First Vaccine Into Human Trials - Intranasal Influenza Vaccine Begins Phase I Clinical Development
BOXMEER, Netherlands, March 13 /PRNewswire-FirstCall/ -- Nobilon, the human
vaccine business unit of Schering-Plough Corporation (NYSE: SGP ), today announced that it has reached an important milestone with the initiation of its first-in-human clinical development program for SCH 900795, a new...
Alimera Reports Favorable Safety and Efficacy Results From the 12-Month Interim Readout of the Human PK Iluvien(TM) Study
ATLANTA, March 12 /PRNewswire/ -- Alimera Sciences, Inc., a privately held biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today reported the interim 12-month safety and efficacy results from the first human
Neuralstem's Human Stem Cells Integrate into Nervous System of Rats with Animal Model of ALS
Make Synaptic Contact with Host Motor Neurons
ROCKVILLE, Md., March 9 /PRNewswire-FirstCall/ -- Transplanted human
neural stem cells (hNSCs) developed by Neuralstem, Inc. (NYSE Alternext US: CUR) made synaptic contacts with the motor neurons of rats with ALS-like symptoms, a paper published i...
Drug Development Program Started Based on CAP(R) Human Cell Line
COLOGNE, Germany, March 3 /PRNewswire/ --
- New Platform May Provide Solutions for Many RA-Patients Around the World
Alloksys Life Sciences BV (Bunnik, The Netherlands), CEVEC
Pharmaceuticals GmbH (Cologne, Germany) and PharmaCell BV (Maastricht, The
Netherlands) announce the sta...
IlluminOss Medical Announces First Human Case Utilizing a Unique, New, Minimally Invasive Technology for Fracture Repair is Performed at Medical Hospital del Trabajadar in Santiago, Chile
Patient Has Mobility Immediately and Makes Rapid Recovery after Procedure Utilizing IlluminOss(TM) Photodynamic Bone Stabilization System
SANTIAGO, Chile, Feb. 24 /PRNewswire/ -- IlluminOss Medical today announced that one of the leading surgeons in Chile, Dr. Sebastian von Unger, has perform...
GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
ATLANTA, Feb. 20 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
(OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded
biopharmaceutical company developing human
vaccines for diseases caused by
HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced
the first injections...
Cloned Human Embryos Successfully Reprogrammed Using Human - But Not Animal - Eggs
New study questions ability of human-animal hybrids to generate stem cells
WORCESTER, Mass., Feb. 2 /PRNewswire-FirstCall/ -- Advanced Cell Technology, Inc. (OTC Pink Sheets: ACTC) and its collaborators reported today that human
oocytes (or 'eggs') have the capacity to extensively reprogram...
Modigene Announces Positive Results of Pilot Toxicity Study of Its Long-Acting Human Growth Hormone hGH-CTP
- Single Injection in Primates Containing 1,000-Times the Dosage Recommended for Humans Shows No Adverse Effects -
- Half-Life and AUC Support the Potential for Weekly or Bi-Monthly Dosing Frequency -
NES-ZIONA, Israel, Jan. 15 /PRNewswire-FirstCall/ -- Modigene Inc. (OTC Bulletin Board:...
2008 Human Research Protection Award Recipients Announced
BETHESDA, Md., Dec. 29 /PRNewswire-USNewswire/ -- The winner of the 2008 Award for Excellence in Human
Research Protection was announced today by Dr. Peter G. Goldschmidt, President and Founder of the Health Improvement Institute.
The winner of the annual award was the University of Texas...
USD 12.5 m Funding for the Development of Intercell's Vaccine Patch System for Pandemic Influenza From U.S. Department of Health and Human Services (HHS)
VIENNA, Austria, Dec. 11 /PRNewswire/ -- Intercell AG (VSE: ICLL) today
announced the execution of a contract modification with the U.S. Department of
Health and Human
Services (HHS). The agreement commits additional funding of
USD 12.5 m for Intercell's Pandemic Influenza program.
SARS Vaccine Achieves Neutralizing Responses in First U.S. Human Trial
SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL ) today announced that results from a Phase I clinical trial of a
DNA vaccine for severe acute respiratory syndrome (SARS), conducted by the
National Institutes of Health (NIH) and published in the November 25 issue of
GeoVax's Phase 2a HIV/AIDS Vaccine Human Trials to Begin in North and South America
ATLANTA, Dec. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
(OTC Bulletin Board: GOVX), an Atlanta-based biotechnology company developing
human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and
other infectious agents, announced today that the launch of its Phase 2a Human
Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
BETHESDA, Md., Nov. 4 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq:
MITI), a biopharmaceutical company developing novel, proprietary antibodies
for the treatment of cancer, inflammation and autoimmune diseases,
presented data from a preclinical study(1) showing cytotoxic activity of
Complete Genomics and the Institute for Systems Biology Announce Partnership to Conduct the First Human Genome Population Study
MOUNTAIN VIEW, Calif. and SEATTLE, Oct. 6 /PRNewswire/ -- Complete
Genomics Inc., a newly launched, third-generation human
company, and the Institute for Systems Biology (ISB) today announced their
partnership to conduct populationwide human
In phase one of ...
Alimera Reports Results From the Six-Month Interim Readout of the Human PK Iluvien(TM) Study
ATLANTA, Oct. 1 /PRNewswire/ -- Alimera Sciences, Inc., a privately
held biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic
pharmaceuticals, today reported the interim month six safety and efficacy
results from the first hum...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following September Meeting of European Committee for Medicinal Products for Human Use (CHMP)
IRVINE, Calif., Sept. 26 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ) today announced that it met with representatives of the
Committee for Medicinal Products for Human
Use (CHMP) and Secretariat of
the European Medicines Agency (EMEA) on September 25th, following the
New Bisphenol A Study Has Limited Capability to Assess Human Health Effects
ARLINGTON, Va., Sept. 16 /PRNewswire-USNewswire/ -- The American
Chemistry Council is aware of a new study on bisphenol A published today in
the Journal of the American Medical Association that reports a statistical
association between urinary bisphenol A concentrations and medical
deCODE and Radboud University Discover Common Variants in the Human Genome Conferring Risk of Bladder Cancer
Detection may be used to complement and target screening for the disease;
findings will be integrated into the deCODEme(TM) personal genome scan.
REYKJAVIK, Iceland, Sept. 14 /PRNewswire-FirstCall/ -- Scientists at
deCODE genetics (Nasdaq: DCGN ) and colleagues at Radboud University Medical
Boston University and The Center for Human Genetics, Inc. Announce Change in Testing Services
BOSTON, Aug. 18 /PRNewswire-USNewswire/ -- Boston University and Aubrey
Milunsky, MB.B.Ch, D.Sc., President of the Center for Human
("CHG") and Director of the Center for Human
Genetics of Boston University,
announced that CHG will no longer offer testing services covered by pat...
ViaViente Demonstrates Cardiovascular Benefits in New Human Trial
By Kathleen J. Burkhalter
BOSTON, Aug. 8 /PRNewswire/ -- Francis, 50, never imagined that
drinking a high anti-oxidant fruit beverage every day could help protect
his health -- in just 1 week. That's what he found out after participating
in a clinical trial near his home...
Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer
EAST SETAUKET, N.Y., Aug. 8 /PRNewswire-FirstCall/ -- Lixte
Biotechnology Holdings, Inc. (OTC Bulletin Board: LIXT) announced today
that lead compounds from each of two different types of drugs being
developed as potential treatment for specific types of brain cancers have
activity against hum...
ProteoTech's Exebryl-1(R) Enters Human Clinical Trials for the Treatment of Alzheimer's Disease
KIRKLAND, Wash., Aug. 7 /PRNewswire/ -- ProteoTech Inc. (ProteoTech)
today announced that it has completed regulatory Investigational New Drug
(IND) requirements and has been cleared by the FDA to initiate its Phase 1
human clinical trial on Exebryl-1(R), a novel small molecule drug targeting
Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
Clinical study planned for advanced or recurrent solid tumors
PRINCETON, N.J., Aug. 5 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) announced today the allowance of an investigational new drug
application (IND) filed with the U.S. Food & Drug Administration (FDA) for
deCODE and SGENE Consortium Discover Deletions in the Human Genome Linked to Risk of Schizophrenia
Findings may provide the foundation for a test to complement standard
clinical diagnosis, potentially enabling earlier intervention and treatment
REYKJAVIK, Iceland, July 30 /PRNewswire-FirstCall/ -- In a major paper
published today in the online edition of the journal Nature, scientists
Vical Announces Breakthrough for Pandemic Influenza DNA Vaccines With Preliminary Human Data
SAN DIEGO, July 17 /PRNewswire-FirstCall/ -- Vical Incorporated
(Nasdaq: VICL ) today announced a breakthrough with preliminary clinical
trial data demonstrating that DNA vaccines can safely achieve significant
immune responses against H5N1 pandemic influenza in humans. DNA vaccines
Insmed Announces First Human Bioequivalence Data for a Follow-on Biologic by a U.S. Company
Company Intends to Request Meeting with FDA Regarding Possible Phase III Trial Based on Human
Data Demonstrating Bioequivalence of INS-19 to Neupogen(R)
RICHMOND, Va., July 10, 2008 /PRNewswire-FirstCall/ -- Insmed Inc.
(Nasdaq: INSM ), a developer of follow-on b...
IDM Pharma Provides Update on Mifamurtide (L-MTP-PE) Regulatory Status Following June Meeting of European Committee for Medicinal Products for Human Use (CHMP)
- Company continues to anticipate CHMP opinion in the third quarter;
L-MTP-PE on track for final European Commission decision in the fourth quarter
IRVINE, Calif., July 1 /PRNewswire-FirstCall/ -- IDM Pharma, Inc.
(Nasdaq: IDMI ) today announced that the CH...
Emisphere Technologies Announces the Launch of a Human Clinical Trial For Oral Parathyroid Hormone (PTH)
Phase I Study to Explore the Effects of Eligen(R) Delivery Technology on Healthy Postmenopausal Women
CEDAR KNOLLS, N.J., June 30 /PRNewswire-FirstCall/ -- Emisphere
Technologies, Inc. (Nasdaq: EMIS ) announced today that Novartis Pharma AG
has launched a Phase I study in...
Positive Mid-Term Results on CryoValve(R) SG Pulmonary Human Heart Valve Presented at Western Thoracic Meeting
ATLANTA, June 30 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY ),
a biomaterials, medical device and tissue processing company, has announced
that positive mid-term performance data on the CryoValve(R) SG
decellularized pulmonary human
heart valve were presented on June 28th at
Alimera Reports Results From the Three-Month Interim Readout of the Human PK Medidur(TM) FA Study
ATLANTA, June 26 /PRNewswire/ -- Alimera Sciences, Inc., a privately
held biopharmaceutical company that specializes in the research,
development and commercialization of prescription ophthalmic
pharmaceuticals, today reported the interim month three safety and efficacy
results from the first ...
Kansas Invests Millions in Innovations to Improve Human Health and Launches Three National Bioscience Programs at BIO'08
SAN DIEGO, June 18 /PRNewswire/ -- Kansas researchers and companies
excel in the human
health biosciences, and $3.7 million in new Kansas
Bioscience Authority (KBA) investments in that sector will support
cutting-edge innovations for the treatment of cancer, HIV, and
osteoporosis, as well as i...